Please login to the form below
Kymriah
This page shows the latest Kymriah news and features for those working in and with pharma, biotech and healthcare.
Novartis announces promising five-year data for leukaemia treatment Kymriah
ALL, we have our strongest evidence yet that one-time treatment with Kymriah has curative potential,”. ... The data shows the potential of Kymriah as a cure, and as the only CAR T-cell therapy available for such patients who have previously had limited
Latest news
-
Novartis’ Kymriah receives FDA approval to treat follicular lymphoma
The single-arm, open-label trial showed that 86% of patients administered Kymriah achieved a response, which included 68% who experienced a complete response. ... The European Commission approved Kymriah in the EU in early May 2022 to treat adult
-
EC approves Novartis’ Kymriah for advanced blood cancer
Kymriah is the first CAR-T cell therapy of its kind approved in the EU for follicular lymphoma. ... The approval of Kymriah in Europe brings patients closer to a potentially definitive therapy, providing us with hope for improved outcomes,” she added.
-
Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz
Novartis has also announced regulatory news for Kymriah (tisagenlecleucel), with the US Food and Drug Administration granting the cancer therapy priority review for patients with relapsed or refractory follicular lymphoma. ... The European Medicines
-
Roche bets on T-cell therapies with Adaptimmune deal
CAR-T therapies including Kymriah (tisagenlecleucel).
-
Yescarta gains first FDA approval for indolent follicular lymphoma
Also approved for the treatment of large B-cell lymphoma is Novartis’ rival CAR-T therapy Kymriah (tisagenlecleucel) and Bristol Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel), which are both approved ... An approval in the first-line
More from news
Approximately 17 fully matching, plus 66 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
By Clive Glover. Since the approval of the first five gene or gene-modified cell therapies in the US – Luxturna, Yescarta, Tecartus, Kymriah and Zolgensma – this new technology has been evolving
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Collaborating with pharma companies, Oxford Biomedica uses its infrastructure to produce other companies’ licensed products, including Novartis’ Kymriah treatment (alongside other undisclosed CAR-T-related products).
-
Cortellis Drugs to Watch in 2020 report
as Kymriah and Yescarta.
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
This is informed by the experience of CAR-T cell therapies, where Novartis’ Kymriah – the first ever CAR-T approved in 2017 – looks set to remain a loss-leader for many ... years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug,
-
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging sign.
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest from PMHub
-
Understanding the evolving CAR-T market
In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... But, Novartis could not retain a monopoly in for long. After the approval of Kymriah, investors
-
Precision paediatrics: Treating patients with CAR-T
There are a number of trials being undertaken throughout the world, but the first licensed product, Novartis’ Kymriah, is now available for the treatment of leukaemia and is live at GOSH.
-
Training the next generation of biotech leaders
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October. ... Kymriah, which make it into routine practice as a first-line treatment.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- How an AI algorithm might save your life
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Innovative Trials
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground”...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
